VANCOUVER, BC, March 8,
2024 /PRNewswire/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSX: NUMI) (OTCQX:
NUMIF), a mental health care company advancing traditional and
innovative behavioral health treatments with a focus on safe,
evidence-based novel therapies, congratulates Mind Medicine
("MindMed" NASDAQ: MNMD, Cboe Canada: MMED) on the positive data
generated from its Phase 2b clinical
trial of MM120 (lysergide d-tartrate) for the treatment of
generalized anxiety disorder ("GAD"). The study showed that four
weeks after a single 100-microgram dose of MM120, 48 percent of the
participants achieved remission and no longer showed clinically
significant anxiety, and 65 percent showed clinically meaningful
improvement. Based on initial clinical data from the Phase
2b trial and the significant unmet
medical need in treating GAD, the U.S. Food & Drug
Administration ("FDA") has designated MM120 for GAD as a
breakthrough therapy. 1
The research was conducted over 20 clinical trial sites with 198
participants. Numinus' Cedar Clinical Research Draper Utah research
clinic was among the highest enrolling sites for the study, with
its clinic at Murray, Utah, also
participating. Dr. Reid Robison,
Numinus' Chief Clinical Officer and Dr. Paul Thielking, Chief Science Officer, were
Principal Investigators.
"We were pleased to participate in this trial of MM120, with the
results indicating a robust and durable improvement for trial
participants with GAD. This is an important development in treating
a condition that is considered the second most common mental health
condition among American adults," said Dr. Robison. "I particularly
commend MindMed for designing a study that removed variables such
as additional medications and psychotherapy so the effects of MM120
were isolated and fully evaluated."
"Our experience in operating clinical trials for leading drug
developers, along with our collaborative approach, was a factor in
our success as top enrolling sites for MindMed," added Payton Nyquvest, Numinus Founder and CEO. "We
look forward to continuing to work with MindMed as it advances its
important research into MM120. With more novel drug treatments
moving through the clinical trial stages with the goal of being
approved, Numinus is well-positioned with an infrastructure that
includes clinical research, treatment clinics and practitioner
training."
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be
well through the development and delivery of innovative mental
health care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus model – including psychedelic research and
clinic care – is at the forefront of a transformation aimed at
healing rather than managing symptoms for depression, anxiety,
trauma, pain and substance use. At Numinus, we are leading the
integration of psychedelic-assisted therapies into mainstream
clinical practice and building the foundation for a healthier
society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-looking
statements
Statements and other information contained in this press
release about anticipated future events constitute forward-looking
statements. Forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate",
"believe", "plan", "estimate", "expect" and "intend" and statements
that an event "may", "will", "should", "could" or "might" occur or
other similar expressions. Forward-looking statements are subject
to risks and uncertainties and other factors that could cause
actual results to differ materially from those contained in the
forward-looking statements, including challenges and uncertainties
inherent in product and/or treatment development and in the
psychedelics industry generally, availably of suitable subjects,
the uncertainties of clinical success, the possibility of adverse
events, and the timeline for the availability of the treatment
under investigation; the laws, challenges and risks involved in the
production of a psychedelics drug; and the uncertainty of the level
of demand, uptake and/or insurance coverage for treatment other
risks that are set forth in and other risks that are set forth in
our annual information form dated November
29, 2023 and available on SEDAR at
www.sedarplus.ca. Forward-looking statements are based on
estimates and opinions of management at the date the statements are
made. Numinus does not undertake any obligation to update
forward-looking statements even if circumstances or management's
estimates or opinions should change except as required by
applicable laws. Investors should not place undue reliance on
forward-looking statements.
______________________________
|
1 https://ir.mindmed.co/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/numinus-wellness-congratulates-mindmed-on-positive-results-from-phase-2b-clinical-trials-of-mm120-for-generalized-anxiety-disorder-302083590.html
SOURCE Numinus Wellness Inc.